T-cell Lymphoma Market Key Players Analysis - 4SC AG, Acrotech Biopharma, Affimed, Bausch Health Companies Inc., Biocryst Pharmaceuticals Inc.

T-cell Lymphoma Market worth $2.89 billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global T-cell Lymphoma Market By Lymphoma Type (Peripheral T-Cell Lymphoma (Cutaneous T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-Immuno-Blastic T-Cell Lymphoma, And Others (Intestinal T-Cell Lymphoma, Follicular T-Cell Lymphoma)) And T-Cell Lymphoblastic Lymphoma), Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, And Others (Antiviral Treatment, Etc.)- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/1312

The global T-cell lymphoma market is projected to grow at a compound annual growth rate (CAGR) of 8.4% from 2022 to 2030, from an estimated value of US$ 1.44 billion in 2021to US$ 2.89 billion by 2030, according to the most recent research by InsightAce Analytic.

One kind of blood cancer that arises in the lymphatic system is lymphoma. B-lymphocytes and T-lymphocytes (T-cells) are two common lymphocytes in the body that have the potential to develop into lymphomas. According to recent studies, malignant T cells regulate the inflammatory milieu, suppress cellular immunity and anti-tumor responses, and create a persistent inflammatory milieu that facilitates the growth of the tumor.
The increasing frequency of autoimmune illnesses and cancer, the aging population,and The rise in radiation-induced lymphoma cancer incidence are
some of the reasons driving the T-cell lymphoma market. Increased R&D Efforts to create efficient T-cell lymphoma-specific therapies, rising healthcare costs, growing public awareness of T-cell lymphoma and its treatments, and growing innovations in T-cell lymphoma-targeted therapies are also anticipated to propel market expansion. The Increasing number of lymphoma cases has prompted academics and pharmaceutical corporations to increase their investments in the development of cutting-edge cancer treatments. To treat peripheral T-cell lymphoma (PTCL) in adults who have received at least one prior therapy, Bristol-Myers Squibb (US) received FDA approval for Istodax® (romidepsin), a histone deacetylase (HDAC) inhibitor, as a monotherapy. Therefore, in the Next years, it is anticipated that the growing R&D activities will present new prospects for the expansion of the T-cell lymphoma market.
Nevertheless, it is anticipated that the high expense of T-cell lymphoma treatments, their intricate production procedures, and some adverse effects will prevent market expansion throughout the projected years.
Due to the rapid adoption of next-generation therapeutic techniques, rising cancer prevalence, and increased research funding, the Asia Pacific region is expected to have considerable growth during the forecast period (2022-2030).

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

Major market players operating in the T-cell lymphoma market include 4SC AG, Acrotech Biopharma, Affimed, Bausch Health Companies Inc., Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Elorac, F. Hoffmann-La Roche Ltd, Genmab A/S, Genor Biopharma, GlaxoSmithKline plc., Innate Pharma, Johnson and Johnson Private Limited, Kyowa Kirin Co., Ltd., Merck and Co. Inc., Novartis AG, Pfizer, Seagen Inc., Secura Bio, Shanghai Junshi Bio, SHIONOGI & Co., Ltd., Solasia, Spectrum Pharmaceuticals Inc., Takeda, Viracta, and Other Prominent Players.

Key developments in the market:
• In October 2021, Merck (US) announced that the FDA had approved KEYTRUDA, its anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (Combined Positive Score [CPS] 1), as determined by an FDA-approved test.
• In May 2021, Remitoro (denileukin diftitox) was approved by Eisai for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and relapsed or refractory cutaneous T-cell lymphoma (CTCL) (CTCL). Eisai got manufacturing and marketing clearance for Remitoro, also known as Ontak in other countries.
• In November 2018, Seagen Inc. (U.S.) received approval for ADCETRIS (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified.
• In August 2018, Poteligeo (mogamulizumab-kpkc) was approved by the US Food and Drug Administration for the therapy of adult patients with relapsed or refractory mycosis fungoides (M.F.) or Sézary syndrome (S.S.), both subtypes of cutaneous t-cell lymphoma (CTCL).

Unlock Your GTM Strategy:https://www.insightaceanalytic.com/customisation/1312

Market Segments

T-cell Lymphoma Market, by Lymphoma Type, 2022-2030 (Value US$ Mn)
• Peripheral T-cell Lymphoma
o Cutaneous T-cell Lymphoma
o Anaplastic Large Cell Lymphoma
o Angio-immuno-blastic T-cell Lymphoma
o Others
 Intestinal T-cell Lymphoma
 Follicular T-cell lymphoma
• T-cell Lymphoblastic Lymphoma

T-cell Lymphoma Market, by Therapy, 2022-2030 (Value US$ Mn)
• Radiotherapy
• Chemotherapy
• Immunotherapy
• Stem Cell Transplantation
• Others (Antiviral Therapy, etc.)

T-cell Lymphoma Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1312

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.